Polaryx Therapeutics, Inc. Common Stock
NASDAQ:PLYXBiotechnology
-$0.02 today
- Market cap
- $80.25M
- Beta
- 0.00
- P/E (TTM)
- -16.7
- EPS (TTM)
- -$0.14
Volume 0.02M
Average 0.34M
PLYX Net Income
Bottom-line profit after all expenses, interest, and taxes.
Polaryx Therapeutics, Inc. Common StockNASDAQ: PLYX
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income remains negative
Q1 FY2026 net income was -$2.54M, compared with -$5.05M a year earlier. Trailing-twelve-month net income was -$6.48M.
Context
- Net income grew in size in 1 of the last 2 fiscal years.
What to watch
Whether net income reaches the consensus estimate of -$5.68M (+36.8%) for the fiscal year ending Dec 2026, a slowdown from the +70.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$2.54M-70.2% QoQ
- Last fiscal yearDec 2025
- -$8.99M+70.4% YoY
- LTMMar 2026
- -$6.48M— YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +49.6% | -40.5% | -90.2 pp |
| 1 year | +70.4% | +36.8% | -33.6 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (8.99M) USD
- Year-over-year change
- +70.4%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (8.99M) | +70.4% |
| FY2024 | 2024-12-31 | (30.36M) | -703.3% |
| FY2023 | 2023-12-31 | (3.78M) | — |
Net Income vs competitors
How PLYX compares with its peers on the latest reported figures
- PLYX's LTM Mar 2026 net income of -$6.48M is the highest of the 8 companies compared; the peer median is -$75.32M.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
PLYXPolaryx Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$6.48M | — | — | — |
| LTM Mar 2026 | -$34.55M | +23.8% | — | — | |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | -$44.1M | +38.9% | — | — |
| LTM Mar 2026 | -$51.59M | -600.9% | — | 186.2% | |
| LTM Mar 2026 | -$75.32M | +6.4% | — | 266.9% | |
| LTM Mar 2026 | -$129.61M | -164.5% | — | — | |
| LTM Mar 2026 | -$162.08M | -206.2% | — | 1363.9% | |
| LTM Mar 2026 | -$246.41M | +26.3% | — | 794858.1% | |
| Peer median (excluding PLYX) | -$75.32M | +6.4% | — | 815.4% | |
Competitors are the stored peer set for PLYX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 |
| Gross Margin | — | — | — |
| Research & Development | 2.77M | 2.81M | 6.27M |
| Selling, General & Admin | 1.01M | 1.54M | 1.56M |
| Operating Expenses | 3.78M | 4.35M | 7.82M |
| Depreciation & Amortization | 0 | 0 | 0 |
| EBITDA | (3.78M) | (30.36M) | (8.99M) |
| EBITDA Margin | — | — | — |
| Operating Income | (3.78M) | (4.35M) | (7.82M) |
| Operating Margin | — | — | — |
| Interest Income | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 |
| Other Income / Expenses | 2K | (26M) | (1.16M) |
| Income Before Tax | (3.78M) | (30.36M) | (8.99M) |
| Pre-Tax Margin | — | — | — |
| Income Tax Expense | 0 | 0 | 0 |
| Net Income | (3.78M) | (30.36M) | (8.99M) |
| Net Margin | — | — | — |
| EPS (Basic) | (0.02) | (0.16) | (0.19) |
| EPS (Diluted) | (0.02) | (0.16) | (0.19) |
| Weighted Avg Shares | 189.37M | 189.37M | 47.34M |
| Weighted Avg Shares (Diluted) | 189.37M | 189.37M | 47.34M |
Polaryx Therapeutics, Inc. Common Stock
NASDAQ:PLYX
Intrinsic Alpha fair value
Locked
Current Price
$1.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.